Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0847 • ACR Convergence 2020
Impact of Hydroxychloroquine Treatment on Immunologic Markers in SLE Depends on Ethnicity
Laurence Magder¹, Daniel Goldman² and Michelle Petri², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: SLE patients with certain immunological markers (i.e., anti-DNA, low complement) are at higher risk of lupus nephritis and those with antiphospholipid antibodies are at…
Abstract Number: 1250 • ACR Convergence 2020
Early Sjögren Antibodies: Potential Biomarker for Abnormal Minor Labial Salivary Gland Biopsy in Juvenile Sjögren’s Syndrome
Akaluck Thatayatikom¹, Sthorn Thatayatikom¹, Indraneel Bhattacharyya², Melissa Elder¹, Renee Modica¹ and Seunghee Cha², ¹Department of Pediatrics, University of Florida, Gainesville, FL, ²College of Dentistry, University of Florida, Gainesville, FL
Background/Purpose: Juvenile Sjögren’s Syndrome (jSS) is a perplexing systemic autoimmune disease in children presenting with positive autoantibodies, glandular, and/ or extraglandular symptoms. In pediatric practice,…
Abstract Number: 1524 • ACR Convergence 2020
Interstitial Lung Disease, Kidney Inflammation and Myositis Are Induced by Transfer of PBMC Derived from Systemic Sclerosis Patients into Rag2-/-/ IL2rg-/- mice
Xiaoyang Yue¹, Frank Petersen¹, Xinhua Yu¹, Gabriela Riemekasten², Peter Lamprecht³, Antje Müller³ and Junping Yin⁴, ¹Priority Area Asthma & Allergy, Research Center Borstel, Airway Research Center North (ARCN), Members of the German Center for Lung Research (DZL), Borstel, Germany, ²University of Lübeck, Department of Rheumatology and Clinical Immunology,, Lübeck, Germany, ³University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ⁴1 Priority Area Asthma & Allergy, Research Center Borstel, Airway Research Center North (ARCN), Members of the German Center for Lung Research (DZL),, Borstel, Germany
Background/Purpose: To explore the pathogenic potential of lymphocytes in systemic sclerosis (SSc) and granulomatosis with polyangiitis (GPA), a humanized mouse model was generated by transferring…
Abstract Number: 0296 • ACR Convergence 2020
Investigating the Differences in ANA Specificities Between Asymptomatic and Symptomatic ANA+ Individuals
Carolina Munoz-grajales¹, Stephenie Prokopec², Dennisse Bonilla³, Earl D. Silverman⁴, Sindhu Johnson³, Arthur Bookman⁵, Zahi Touma⁶, Zareen Ahmad⁷, Linda Hiraki⁸, Paul Boutros⁹, Andrzej Chruscinski¹⁰ and Joan Wither³, ¹University of Toronto, Toronto, Canada, ²Ontario Institute for Cancer Research, Toronto, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁵Division of Rheumatology, University Health Network; 8Department of Medicine, University of Toronto; Division of Rheumatology, Toronto, Canada, ⁶University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada, ⁷Department of Medicine, University of Toronto; Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children; Department of Medicine, University of Toronto, Toronto, Canada, ⁹Department of Immunology, University of Toronto; Department of Medical Biophysics, University of Toronto; Department of Pharmacology and Toxicology, University of Toronto; Department of Human Genetics, University of California; Department of Urology, University of California; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California; Institute for Precision Health, University of California; Jonsson Comprehensive Cancer Centre, University of California, Toronto, Canada, ¹⁰Multi-Organ Transplant Program, University Health Network, Toronto, Canada
Background/Purpose: Within the Anti-Nuclear Antibody (ANA) associated Systemic Autoimmune Rheumatic Diseases (SARD), such as Systemic Lupus Erythematous (SLE), Sjögren’s Syndrome (SS), and Systemic Sclerosis (SSc),…
Abstract Number: 0916 • ACR Convergence 2020
Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis
Fiza Ahmed¹, Svetlana Nihtyanova¹, Stamatia Chatzinikolaou², Voon Ong¹, Charles Murray² and Christopher Denton³, ¹Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ²Department of Gastroenterology, Royal Free London Foundation Trust, UK, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Patients with systemic sclerosis (SSc) frequently experience gastrointestinal (GI) symptoms, ranging from mild to debilitating in severity. Better prediction of those most at risk…
Abstract Number: 1261 • ACR Convergence 2020
Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Antiphospholipid syndrome (APS) has been classified as the development of venous and/or arterial thromboses, and/or pregnancy morbidity, in the presence of persistently raised levels…
Abstract Number: 1574 • ACR Convergence 2020
Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review
Nilasha Ghosh¹, Karmela Kim Chan², Bridget Jivanelli³ and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: Although immune checkpoint inhibitor (ICI) cancer treatments are known to activate cytotoxic T-cells, autoantibodies may also contribute to the development of immune-related adverse events…
Abstract Number: 0299 • ACR Convergence 2020
The Minor Protective Allele at rs1876453 Is Associated with Increased Age of Onset of Systemic Lupus Erythematosus
Ani Oganesyan¹, Jennifer Kelly², Stuart Glenn², Adam Adler², Adrienne Williams³, Mary Comeau⁴, Julia Ziegler⁵, Miranda Marion⁵, Marta Alarcón-Riquelme⁶, Graciela Alarcón⁷, Juan-Manuel Anaya⁸, Sang-Cheol Bae⁹, Dam Kim⁹, Lee Hye-Soon⁹, Lindsey Criswell¹⁰, Barry Freedman¹¹, Gary Gilkeson¹², Joel Guthridge¹³, Chaim Jacob¹⁴, Judith James¹⁵, Diane Kamen¹⁶, Joan Merrill¹⁷, Kathy Moser Silvis¹⁸, Timothy Niewold¹⁹, Michelle Petri²⁰, Rosalind Ramsey-Goldman²¹, John Reveille²², Hal Scofield²³, Anne Stevens²⁴, Luis Vilá²⁵, Timothy Vyse²⁶, Kenneth Kaufman²⁷, John Harley²⁸, Carl Langefeld⁵, Patrick Gaffney², Elizabeth Brown²⁹, Jeffrey Edberg⁷, Robert Kimberly⁷, Betty Tsao¹², Daniela Ulgiati³⁰, Kenneth Jones³¹ and Susan Boackle³², ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Biostatistical Sciences and Center for Public Health Genomics Wake Forest School of Medicine, Winston-Salem,, NC, ⁴Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine; MC Analytics, Winston-Salem, NC, ⁵Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica, Granada (GENYO), Granada, Spain, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogotá, Colombia, ⁹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁰Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ¹¹Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem,, NC, ¹²Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oaklahoma, OK, ¹⁴Department of Medicine, University of Southern California, Los Angeles, CA, ¹⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ¹⁶Medical University of South Carolina, Charleston, SC, ¹⁷Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²²Department of Internal Medicine, University of Texas, Houston, TX, ²³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Charleston, SD, ²⁴Janssen Pharmaceuticals, Spring House, PA, ²⁵Division of Rheumatology, Department of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ²⁶Division of Genetics and Molecular Medicine and Immunology, King’s College, London, United Kingdom, ²⁷Cincinnati Children’s Hospital Medical Center;US Department of Veterans Affairs Medical Center, Cincinnati, OH, ²⁸Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ²⁹Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, ³⁰School of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, Australia, ³¹Harold Hamm Diabetes Center, University of Oklahoma Health Science Center, Oklahoma City, OK, ³²Division of Rheumatology, University of Colorado School of Medicine; Denver Veterans Affairs Medical Center, Aurora, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is a clinically heterogenous autoimmune disease characterized by autoantibody- and complement-mediated inflammatory damage to multiple organ systems. We previously showed…
Abstract Number: 0922 • ACR Convergence 2020
Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex
Christopher Mecoli¹, Brittany Adler², Qingyuan Yang², Laura Hummers³, Antony Rosen², Livia Casciola-Rosen⁴ and Ami Shah⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Univerisity, Ellicott City, MD, ⁴Johns Hopkins University, Johns Hopkins University, MD, ⁵Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: The aim of this study is to describe four of the most common autoantibodies against components of the Th/To complex: hPOP1, RPP25, RPP30, and…
Abstract Number: 1262 • ACR Convergence 2020
Single LAC Positivity versus Double and Triple Positivity for Thrombosis in SLE
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose:Antiphospholipid syndrome (APS) is classified as the development of venous and/or arterial thromboses, and pregnancy morbidity, in the presence of antiphospholipid antibodies (aPL); lupus anticoagulant,…
Abstract Number: 1606 • ACR Convergence 2020
Mortality with Idiopathic Inflammatory Myositis in an Academic Hospital Setting: A Five-year Retrospective Study
Jaspreet Kaler¹, Zareen Vaghaiwalla², Gurjit Kaeley³ and Myint Thway⁴, ¹University of Florida - Jacksonville, Jacksonville, FL, ²University of Florida Jacksonville, Jacksonville, FL, ³University of Florida College of Medicine - Jacksonville, Jacksonville, FL, ⁴University of Florida- Jacksonville, ponte vedra, FL
Background/Purpose: Idiopathic inflammatory myositis is a diverse group of muscle diseases characterized by muscle inflammation and dysfunction. Approximately 3-7/100,000 cases are diagnosed per year in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.